Cell therapy developer ArsenalBio raises $325 million
Arsenal Biosciences has closed an oversubscribed $325 million Series C financing round to support its development of CAR T-cell therapies for solid tumours.
The funding round included new investors ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures (NVIDIA’s venture capital arm), Luma Group, funds and accounts advised by T Rowe Price Associates, Rock Springs Capital, among others.
The company also had ongoing support from existing investors the Parker Institute for Cancer Immunotherapy (PICI), SoftBank Vision Fund 2, Bristol-Myers Squibb Company, Westlake Village BioPartners, Kleiner Perkins, Byers Capital, and Hitachi Ventures.
Proceeds from the financing will be used to advance ArsenalBio’s lead programmes as the company builds its pipeline of therapeutic candidates for solid tumour cancers based on its proprietary T cell engineering technology, including logic gating.
“Our initial clinical trials and preclinical studies have shown the promise of our T cell engineering approach and have given us the confidence to broaden the application of our technology to address additional cancer types,” said Ken Drazan, ArsenalBio’s Co-Founder, CEO and Chairman. “This new investment enables us to continue our development roadmap, scale up our manufacturing capabilities, and invest in new avenues for innovation in T cell medicine.”
Solid tumour treatment pipeline
ArsenalBio’s pipeline includes potential therapies for ovarian, kidney, and prostate cancers, as well as other solid tumours being co-developed through a collaboration with Bristol-Myers Squibb.
The fundraising follows ArsenalBio’s recent entry into clinic with its second T cell product candidate, AB-2100, being studied in a Phase I/II clinical trial for clear-cell renal cell carcinoma (ccRCC). The candidate has been granted Fast Track designation by the US Food and Drug Administration (FDA).
The company says it aims to build the industry’s largest DNA library of potential therapeutic enhancing integrated circuits, incorporating logic gating for improved tumour targeting and synthetic features enabling multiple pharmaceutical functions.
Diana Spencer, Senior Digital Content Editor, DDW
